Pfizer Inc
Executive Salaries, Bonuses, Stock Options, and Other Compensation

Name and

Principal Position

                            (a)

($)
(c)

($)

(d)

($)

(e)

I. Read
Group President, Worldwide Biopharmaceutical Businesses (until December 5, 2010); President and Chief Executive Officer thereafter

500,000

F. D'Amelio
EVP, Business Operations and Chief Financial Officer

600,000

M. Dolsten⁽⁷⁾
President, Worldwide Research and Development

F. Lewis-Hall⁽⁸⁾
EVP, Chief Medical Officer

G. Germano⁽⁹⁾
President and General Manager, Specialty Care and Oncology

J. Kindler⁽¹⁰⁾
former Chairman and Chief Executive Officer (until December 5, 2010)

(1) The amounts shown in this column represent one-time cash incentive awards made in 2010 and 2009. The 2010 amounts shown for Dr. Dolsten and Mr. Germano relate to sign-on cash incentive awards of $2.1 million and $750,000, respectively, under their employment offers. Dr. Dolsten’s award of $2.1 million was payable in two equal installments in 2009 and 2010; the first installment of $1.05 million was paid upon his hire and the second installment was paid on the first anniversary of his hire date. If his employment is voluntarily terminated prior to the second anniversary of his hire date, he will be required to repay $1.05 million to the Company. Mr. Germano’s cash incentive award of $750,000 was paid on the first anniversary of his hire date. If his employment is voluntarily terminated prior to the second anniversary of his hire date, he will be required to repay $750,000 to the Company. Also shown for 2010 is the first installment of Dr. Lewis-Hall’s sign-on cash incentive award of $2.0 million, which is payable in two equal installments in 2010 and 2011. If her employment is voluntarily terminated prior to the third anniversary of her hire date, she will be required to repay $1.0 million to the Company. In 2009, Dr. Lewis-Hall received a one-time sign-on cash incentive award of $1.06 million, and her 2009 annual incentive was guaranteed at target ($566,700). If her employment is voluntarily terminated prior to the second anniversary of her commencement of employment, she will be required to repay $530,000 to the Company. In October 2009, Messrs. Read and D’Amelio received special one-time cash and equity incentive awards totaling $1.0 million and $1.2 million, respectively, in recognition of their performance and leadership in connection with the successful completion of the Wyeth acquisition on October 15, 2009, of which 50% was paid in cash.

(2) The amounts shown in this column represent the grant date fair values for the RSU, PSA and STI Shift Awards granted in 2010, 2009 and 2008, respectively, including RSUs granted to Messrs. Read and D’Amelio in connection with the Wyeth transaction (see Note 1). The 2008 amounts were recalculated from those shown in the 2009 Proxy Statement to reflect the grant date fair values for the 2008 awards, as required by SEC rules beginning in 2010. Further information regarding the 2010 awards is included in the “2010 Grants of Plan-Based Awards” and “2010 Outstanding Equity Awards at Fiscal Year-End” tables elsewhere in this Proxy Statement. The grant date fair values of the performance-based awards reflected in this column (the PSA and STI Shift Awards) are the target payouts based on the probable outcome of the performance condition, determined as of the grant date. The maximum potential values of the PSA and STI Shift Awards would be 200% of target, which in the case of Mr. Read’s PSA and STI Shift Awards would be $1,871,884 and $1,750,000, respectively; in the case of Mr. D’Amelio’s PSA and STI Shift Awards would be $1,871,884 and $1,750,000, respectively; in the case of Dr. Dolsten’s PSA and STI Shift Awards would be $1,390,540 and $1,300,000, respectively; in the case of Dr. Lewis-Hall’s PSA and STI Shift Awards would be $962,688 and $900,000, respectively; in the case of Mr. Germano’s PSA and STI Shift Awards would be $791,540 and $740,000, respectively; and in the case of Mr. Kindler’s PSA Award would be $6,417,830 (his STI Shift Award was settled in March 2011 in connection with his retirement in December 2010). Information related to the performance-based award program is included in “Rewarding Performance—2010 Performance Share Awards” elsewhere in this Proxy Statement. The grant date fair values have been determined based on the assumptions and methodologies set forth in the Company’s 2010 Financial Report (Note 15, Share-Based Payments).

(3) The amounts shown in this column represent the grant date fair values of the TSRUs awarded in 2010, 2009 and 2008, respectively, including the TSRUs granted to Messrs. Read and D’Amelio in connection with the Wyeth transaction (see Note 1). The 2008 amounts were recalculated from those shown in the 2009 Proxy Statement to reflect the grant date fair value of the 2008 awards, as required by SEC rules beginning in 2010. The grant date fair values have been determined based on the assumptions and methodologies set forth in the Company’s 2010 Financial Report (Note 15, Share-Based Payments).

(4) The amounts shown in this column represent annual cash incentive awards made to the Named Executive Officers under the GPP. Further information regarding the 2010 awards is included in the “2010 Annual Cash Incentive Awards” table elsewhere in this Proxy Statement.